SEC Form 4 · accession 0001104659-17-041901

Nabriva Therapeutics Legacy plc · NBRV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 23, 2017

Accepted (ET)

Jun 27, 2017 · 9:54 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001703287

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares	Jun 23, 2017	J	31,790	$0.00	A	31,790	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option^F3,F2	—	Jun 23, 2017	J	40,000	A	—	Jul 5, 2025	Ordinary Shares	40,000	40,000	D
Stock Option^F5,F4	—	Jun 23, 2017	J	10,100	A	—	Aug 25, 2026	Ordinary Shares	10,100	10,100	D

F1Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
F2This option was granted on July 6, 2015. Vesting began on July 31, 2015 and ends on July 31, 2019. Twenty-five percent (25%) of the option vested on July 31, 2016, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
F3The exercise price is 6.618 Euro.
F4This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
F5The exercise price is 6.634 Euro.